Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
about
Amyloid diseases of the heart: current and future therapiesAn overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failureSerum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.The evolving use of serum free light chain assays in haematology.Amyloidosis: pathogenesis and new therapeutic options.Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationCurrent perspectives on cardiac amyloidosis.Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell TransplantationClinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Perspectives in treatment of AL amyloidosis.Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisCurrent trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.The Imaging Diagnosis of Less Advanced Cases of Cardiac Amyloidosis: The Relative Apical Sparing PatternSerum free light chain analysis in multiple myeloma and plasma cell dyscrasias.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.New and developing therapies for AL amyloidosis.Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy.Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.Preclinical development of siRNA therapeutics for AL amyloidosis.Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patientsOutcome of autologous stem cell transplantation for AL amyloidosis in the UK
P2860
Q27023836-774EC945-F709-41D3-847A-696091DBA6C8Q33304297-A07407B2-9106-45B5-8A31-CC573452C419Q34240595-D31919B2-A747-4B46-A9B6-B2A3065BFDCFQ34450428-BA947F04-C416-4610-9FDA-186CAB1EFCB9Q34758218-F02D0FBD-8EE3-425E-96E6-580DAE50D45BQ35111771-08EC5EE3-85E1-4B6A-825B-D04E1317FFC1Q35848844-0BCAAABC-DF08-48F2-A325-6C0710ECAD35Q35849610-87522B27-930E-4C04-AC6C-AFAECD328856Q35964900-3B474F07-0049-425E-BBAA-744D29FFC593Q36384780-6ED72602-BE2B-4621-A4DF-EA83FD790676Q36712121-51D46101-4E44-40A1-BB31-394F78E9C940Q36779759-63E59029-C767-463F-A203-FDED0238640DQ36892637-59FCE83D-CD21-4D5D-ACF3-6FAF1B692165Q36910372-9FED4654-52D5-445E-BE40-FA81997EF041Q37045885-6F22A322-D727-41A3-85A2-93C07CF60967Q37172003-CD584D38-404C-48A6-8A3F-76EA53720AD6Q37370051-06D580A7-1410-4E5C-90CA-D163FB8F04C2Q37697277-713B3568-633F-41BD-B1FD-D72C761C3797Q37821496-30A67A11-E064-47FE-BD1A-5CBB45FA527EQ37904673-65016561-97FB-42F7-9933-C57FF0368EF6Q37995198-F60D4565-F725-47E5-8B92-58DDC45650EDQ38168869-B0EA3AE1-6A56-4DE8-825B-82D60EB0E2B1Q38779623-03B02F50-FFA7-4AE8-8351-4290E8160E01Q38851025-068AF2C9-2B30-4684-B91D-A2A7FCCF068DQ40973226-998B3DC1-1F43-4962-998F-11CA4860BFB4Q42543905-3D723570-9E84-4C70-B7FE-D7AB8DADE01DQ42867066-C51F04DA-3085-4BA9-B8E0-2BC6E6332CDEQ44060632-5712F418-7CFE-47C2-9700-DD6ACFADDCE3Q44468671-D71904A7-096A-41C0-88CD-BF2A002B1AF2Q46251291-52002133-EEC0-4431-9A39-E2E6306B35ACQ46680983-CC92A41F-21DE-4CC1-A9DF-2ABE50E9F7D3Q46980729-2B08F5F4-8CDB-47A6-AA81-33994AA4A3B2Q58853169-FB21F734-56AC-4E38-B28E-0AFE674EF85AQ58853185-A410E03B-8E55-43AE-AC86-12435FEA126E
P2860
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Serum free light-chain respons ...... for AL (primary) amyloidosis.
@en
Serum free light-chain respons ...... em cell transplantation for AL
@nl
type
label
Serum free light-chain respons ...... for AL (primary) amyloidosis.
@en
Serum free light-chain respons ...... em cell transplantation for AL
@nl
prefLabel
Serum free light-chain respons ...... for AL (primary) amyloidosis.
@en
Serum free light-chain respons ...... em cell transplantation for AL
@nl
P2093
P2860
P356
P1476
Serum free light-chain respons ...... for AL (primary) amyloidosis.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BMT.1705106
P407
P577
2005-10-01T00:00:00Z
P5875
P6179
1027034985